NCT05495048 is a NA clinical trial of NOSES VIIIA in Colon Cancer, sponsored by Shanghai Minimally Invasive Surgery Center.

Who is sponsoring NCT05495048?

NCT05495048 is sponsored by Shanghai Minimally Invasive Surgery Center.

What drugs are being tested in NCT05495048?

Interventions in NCT05495048: NOSES VIIIA, laparoscopic surgery with mini-laparotomy.

What condition does NCT05495048 study?

NCT05495048 studies Colon Cancer.

Is NCT05495048 still recruiting?

NCT05495048 is currently recruiting now. Last updated 26 February 2024.

Last reviewed 2024-02-26 · How we verify

NCT05495048

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transvaginal NOSES Versus Conventional Laparoscopic Surgery for Right Hemicolectomy

Recruiting now NA Last updated 26 February 2024

What this trial tests

NA trial testing NOSES VIIIA in Colon Cancer in 356 participants. Currently enrolling.

Timeline

1 July 2023

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	Shanghai Minimally Invasive Surgery Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	356
Start date	1 July 2023
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

NOSES VIIIA
laparoscopic surgery with mini-laparotomy

Conditions studied

Colon Cancer — all drugs for Colon Cancer →

Sponsor

Shanghai Minimally Invasive Surgery Center — full company profile →

Who can join

Adults 18 to 75, female only, with Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is controversial that totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction (NOSES VIIIA) can provide non-inferior oncological outcomes compared to conventional laparoscopic surgery with mini-laparotomy in the treatment of right colon cancer. We aim to carry out a multicenter, open-lable, parallel, non-inferiority, phase III, randomized controlled clinical trial, which enrolls 356 female patients with cT1-3NxM0 right colon adenocarcinoma. They are randomly assigned to the experimental group (NOSES VIIIA) or the control group (laparoscopic surgery with mini-laparotomy) in a 1:1 ratio. Perioperative indicators, pathological results, quality of life and cosmetic evaluation will be compared between the two groups. Then, a three-year follow-up of these patients will provide evidence for long-term oncological outcomes of NOSES VIIIA.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Natural orifice specimen extraction surgery versus small-incision assisted laparoscopic radical right hemicolectomy.
Yu M, Cai Z, Zhou H, Fingerhut A, et al · · 2023 · cited 4× · PMID 38108112 · DOI 10.2217/fon-2023-0769

Verify or expand the search:

Other recruiting trials for Colon Cancer

Currently open trials in the same condition.

NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
NCT07279077 — Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advance · Phase 2 · recruiting
NCT07205965 — The Effect of Acceptance and Commitment Approach-Based Psychoeducation in Cancer Survivors · NA · active not recruiting
NCT07285356 — Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy · NA · recruiting
NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting

Other Shanghai Minimally Invasive Surgery Center trials

Trials by the same sponsor.

NCT07076979 — Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetB · recruiting
NCT07068529 — Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer：M · recruiting
NCT06746298 — A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer · not yet recruiting
NCT04620473 — Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer · Phase 2 · withdrawn
NCT05352165 — The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemot · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05495048 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Minimally Invasive Surgery Center
Last refreshed: 26 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing